High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study

Published:2023-02 Issue: Volume:176 Page:98-102
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Conforti Fabio,Pala Laura,Vivanet Grazia,Corti Chiara,Catania Chiara,Maiettini Daniele,Varano Gianluca,Di Venosa Benedetta,Curigliano Giuseppe,Salvini Piermario,Berardi Rossana,Ballatore Zelmira,De Pas Tommaso Martino

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference20 articles.

1. Thymic epithelial tumors: From biology to treatment;Conforti;Cancer Treat Rev.,2020

2. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial;Thomas;Lancet Oncol.,2015

3. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial;Sato;Lancet Oncol.,2020

4. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study;Giaccone;Lancet Oncol.,2018

5. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial;Cho;J Clin Oncol.,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP